Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$97.94

-1.53 (-1.54%)

, ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

09:10
08/07/18
08/07
09:10
08/07/18
09:10

BioMarin competitive positioning 'improved measurably,' says Piper Jaffray

Spark Therapeutics' (ONCE) update this morning for hemophilia A candidate SPK-8011 was disappointing both efficacy- and safety-wise, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Spark Fails to Ignite; Valrox Competitive Positioning Just Improved Measurably." He believes the news "goes a long way" to putting this potential threat to BioMarin (BMRN) "to bed." The analyst is incrementally positive on BioMarin's competitive positioning in hemophilia A and keeps an Overweight rating on the shares with a $120 price target. The Spark data compares unfavorably to BioMarin's valrox, Raymond writes. He remains a buyer of BioMarin with an Overweight rating and $120 price target. The stock in premarket trading is up $5.55 to $103.50.

BMRN

BioMarin

$97.94

-1.53 (-1.54%)

ONCE

Spark Therapeutics

$77.63

3.84 (5.20%)

  • 07

    Aug

  • 07

    Aug

  • 10

    Sep

  • 12

    Sep

BMRN BioMarin
$97.94

-1.53 (-1.54%)

05/29/18
SBSH
05/29/18
NO CHANGE
Target $108
SBSH
Buy
BioMarin price target raised to $108 from $100 at Citi
Citi analyst Robyn Karnauskas raised her price target for Biomarin Pharmaceutical to $108 following the approval of Palynziq. The drug received a broad label and monitoring only for a single dose can accelerate patient uptake, Karnauskas tells investors in a research note. She keeps a Buy rating on BioMarin shares.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $120
PIPR
Overweight
BioMarin price target raised to $120 from $114 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for BioMarin Pharmaceutical to $120 and keeps an Overweight rating on the name following the company's "solid" Q2 results. The analyst believes the Palynziq launch is going well and says BioMarin provided incrementally positive updates for hemophilia gene therapy candidate valrox. He sees a "credible chance" that BioMarin could file early for accelerated approval on valrox Phase 1 data. Raymond continues to like to setup for the stock and would be a buyer to levels approaching $120.
08/06/18
WEDB
08/06/18
NO CHANGE
Target $120
WEDB
Outperform
BioMarin price target raised to $120 from $115 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for BioMarin to $120 from $115 after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
08/07/18
STFL
08/07/18
INITIATION
Target $114
STFL
Buy
BioMarin transferred with a Buy at Stifel
Stifel transferred coverage of BioMarin to analyst Paul Matteis, who set a Buy rating and $114 price target on the shares. He sees the approved product base having a path to about $2B in 2019 revenue, which provides a share floor of about $80 ahead of a handful of clinical catalysts during the next 12-18 months, Matteis tells investors. BioMarin is better positioned than most mature biotechs in terms of drug pricing pressure and competition risk, added the analyst.
ONCE Spark Therapeutics
$77.63

3.84 (5.20%)

07/16/18
CANT
07/16/18
NO CHANGE
Target $103
CANT
Overweight
Start of Pfizer trial encouraging for Spark Therapeutics, says Cantor Fitzgerald
After Spark Therapeutics (ONCE) announced that partner Pfizer (PFE) initiated a Phase 3 study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, Cantor Fitzgerald analyst Elemer Piros said he was encouraged that the program transfer is on track and he remains bullish on the fidanacogene elaparvovec program. He reiterates his Overweight rating and $103 price target on Spark shares.
07/19/18
RBCM
07/19/18
DOWNGRADE
RBCM
Sector Perform
Spark Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
07/19/18
RBCM
07/19/18
DOWNGRADE
Target $75
RBCM
Sector Perform
Spark Therapeutics cut to Sector Perform at RBC Capital on SPK-801 concern
As reported earlier, RBC Capital analyst Kennen MacKay downgraded Spark Therapeutics to Sector Perform from Outperform and kept his $75 price target. The analyst notes that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." McKay also cites the possibility of regulatory delays to gain approval for sale of Luxturna among the risks for Spark Therapeutics.
07/19/18
07/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Hold at Needham with analyst Rajvindra Gill saying the stock remains overvalued in spite of its 16% decline from the the June 2017 peak. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at UBS with analyst Steven Strycula saying the company's reinvestment cycle limits earnings and stock upside. 3. Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying his crane check was good but not great, with demand appearing to sequentially flatten. 4. Spark Therapeutics (ONCE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Kennen MacKay saying that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." 5. Hyatt (H) downgraded to Hold from Buy at Berenberg with analyst El Kassir saying Hyatt continues to benchmark well on its pipeline, however, there is little scope for future growth to accelerate from current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

04:00
06/18/19
06/18
04:00
06/18/19
04:00
General news
EGB yields decline with Treasury rates »

EGB yields decline with…

03:15
06/18/19
06/18
03:15
06/18/19
03:15
General news
FX Action: USD-CAD has settled near 1.3400 »

FX Action: USD-CAD has…

02:45
06/18/19
06/18
02:45
06/18/19
02:45
General news
FX Update: Sterling has hit fresh lows, and the yen has remained bid »

FX Update: Sterling has…

02:00
06/18/19
06/18
02:00
06/18/19
02:00
General news
Asian Market Wrap »

Asian Market Wrap:…

GE

General Electric

$10.04

-0.2 (-1.95%)

21:05
06/17/19
06/17
21:05
06/17/19
21:05
Periodicals
General Electric to cut another 450 jobs in Switzerland, Reuters says »

General Electric will lay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$86.25

-1.52 (-1.73%)

20:00
06/17/19
06/17
20:00
06/17/19
20:00
Hot Stocks
Arthur J. Gallagher acquires P2 Group, terms not stated »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

AGLNF

AGL Energy

$0.00

(0.00%)

19:28
06/17/19
06/17
19:28
06/17/19
19:28
Upgrade
AGL Energy rating change at Macquarie »

AGL Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

, RUN

Sunrun

$17.09

0.64 (3.89%)

19:02
06/17/19
06/17
19:02
06/17/19
19:02
Upgrade
SunPower, Sunrun, SolarEdge rating change at Goldman Sachs »

SunPower, Sunrun upgraded…

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

SEDG

SolarEdge

$56.58

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

, PHAS

PhaseBio

$12.25

0.74 (6.43%)

18:48
06/17/19
06/17
18:48
06/17/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: MoneyGram (MGI)…

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

PHAS

PhaseBio

$12.25

0.74 (6.43%)

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

CALA

Calithera Biosciences

$5.87

0.64 (12.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 18

    Jun

  • 19

    Jun

AAPL

Apple

$193.90

1.06 (0.55%)

18:44
06/17/19
06/17
18:44
06/17/19
18:44
Periodicals
Apple's tvOS 13 beta 2 includes Picture-in-Picture support, 9to5Mac reports »

Apple's tvOS 13 beta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$56.58

0.09 (0.16%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change at Goldman Sachs »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change at Goldman Sachs »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change at Goldman Sachs »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change at UBS »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.